In the realm of CRC, combined treatment with the CDK4/6 inhibitor palbociclib and MEK inhibitor binimetinib was recently shown to synergistically suppress tumor growth across a panel of RAS-mutated CRC patient-derived xenograft models [84]. This evidence concerns the gene MAP2K7 and neoplasm.